Portage Biotech (NASDAQ:PRTG) Shares Scheduled to Reverse Split on Thursday, August 15th

Portage Biotech Inc. (NASDAQ:PRTG)’s stock is scheduled to reverse split on the morning of Thursday, August 15th. The 1-20 reverse split was announced on Tuesday, August 13th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, August 14th.

Portage Biotech Trading Down 18.1 %

NASDAQ PRTG traded down $0.03 during trading on Tuesday, hitting $0.12. The stock had a trading volume of 1,041,854 shares, compared to its average volume of 446,650. Portage Biotech has a one year low of $0.11 and a one year high of $3.10. The stock has a 50 day simple moving average of $0.21 and a 200 day simple moving average of $0.37. The stock has a market capitalization of $2.19 million, a price-to-earnings ratio of -0.01 and a beta of 1.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.78 and a current ratio of 2.78.

About Portage Biotech

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.